Petros Agathangelou

Dr. Petros Agathangelou


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 November 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AQAnnalisa Quattrocchi
Annalisa Quattrocchi
IMIoannis Mamais
Ioannis Mamais
Constantinos TsioutisConstantinos Tsioutis
Constantinos Tsioutis
ECEirini Christaki
Eirini Christaki
CCCostas Constantinou
Costas Constantinou
Georgios NikolopoulosGeorgios Nikolopoulos
Georgios Nikolopoulos
Coronavirus disease 2019 (COVID-19) has significantly affected the well-being of individuals worldwide. We herein describe the epidemiology of COVID-19 in the Republic of Cyprus during the first epidemic wave (9 March–3 May 2020). We analyzed surveillance data from laboratory-confirmed cases, including targeted testing and population screening. Statistical analyses included logistic regression. During the surveillance period, 64,136 tests (7322.3 per 100,000) were performed, 873 COVID-19 cases were diagnosed, and 20 deaths were reported (2.3%). Health-care workers (HCWs) represented 21.4% of cases. Overall, 19.1% of cases received hospital care and 3.7% required admission to Intensive Care Units. Male sex (adjusted Odds Ratio (aOR): 3.04; 95% Confidence Interval (CI): 1.97–4.69), increasing age (aOR: 1.56; 95%CI: 1.36–1.79), symptoms at diagnosis (aOR: 6.05; 95%CI: 3.18–11.50), and underlying health conditions (aOR: 2.08; 95%CI: 1.31–3.31) were associated with hospitalization. For recovered cases, the median time from first to last second negative test was 21 days. Overall, 119 primary cases reported 616 close contacts, yielding a pooled secondary attack rate of 12% (95%CI: 9.6–14.8%). Three population-based screening projects, and two projects targeting employees and HCWs, involving 25,496 people, revealed 60 positive individuals (0.2%). Early implementation of interventions with targeted and expanded testing facilitated prompt outbreak control on the island.

25 June 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
SKSotiris Kyriakou
Sotiris Kyriakou
AKArgyris Kyriakou
Argyris Kyriakou
MNMarilina Neokleous
Marilina Neokleous
EBEREN OZAN BAKIR
EREN OZAN BAKIR
PAPetros Agathangelou
Petros Agathangelou
Georgios P. GeorghiouGeorgios P. Georghiou
Georgios P. Georghiou
Percutaneous coronary intervention (PCI) treats focal coronary obstruction by compressing plaque, injuring the vessel wall and placing a metallic or bioresorbable scaffold. Most treated segments heal, but a small minority enter a prolonged, excessive or unstable repair state that contributes to in-stent restenosis (ISR), in-stent neoatherosclerosis and stent thrombosis (ST). Human evidence is strongest for delayed healing, uncovered struts, macrophage-rich neoatherosclerosis and hypersensitivity-associated late thrombosis, whereas routine immune biomarker-guided care remains unsupported. The narrowed lumen is only the visible endpoint; beneath it sits vascular repair shaped by de-vice-material exposure, local haemodynamics and host immunity. Endothelial denuda-tion and platelet activation initiate fibrin deposition, complement signalling and dam-age-associated molecular-pattern (DAMP) release. Neutrophils, monocytes and macro-phages dominate early, followed by lymphocytes and vascular smooth muscle cells that remodel the repair compartment. Drug-eluting stents (DES) have markedly reduced early neointimal hyperplasia, yet selected late failures still involve delayed endothelial recovery, chronic peristrut inflammation, hypersensitivity and neoatherosclerotic transformation. Immune biology is useful at the bedside only when interpreted with procedural context, device design and patient phenotype. Imaging-defined endpoints and paired immune phenotyping are therefore needed to guide treatment by mechanism instead of angiography or isolated biomarkers.

9 July 2026 in Immuno
Verified
Journal Article
Open access
PDF file
Sotiris KyriakouSotiris Kyriakou
Sotiris Kyriakou
AKArgyris Kyriakou
Argyris Kyriakou
MNMarilina Neokleous
Marilina Neokleous
EBEREN OZAN BAKIR
EREN OZAN BAKIR
PAPetros Agathangelou
Petros Agathangelou
Georgios P. GeorghiouGeorgios P. Georghiou
Georgios P. Georghiou
Percutaneous coronary intervention (PCI) treats focal coronary obstruction by compressing plaque, injuring the vessel wall, and placing a metallic or bioresorbable scaffold. Most treated segments heal, but a small minority enter a prolonged, excessive, or unstable repair state that contributes to in-stent restenosis (ISR), in-stent neoatherosclerosis, and stent thrombosis (ST). Human evidence is strongest for delayed healing, uncovered struts, macrophage-rich neoatherosclerosis, and hypersensitivity-associated late thrombosis, whereas routine immune biomarker-guided care remains unsupported. The practical question addressed here is therefore not whether inflammation participates, which is established, but which immune signals, read together with intravascular imaging, could realistically change post-PCI management. The narrowed lumen is only the visible endpoint; beneath it sits vascular repair shaped by device-material exposure, local haemodynamics, and host immunity. Endothelial denudation and platelet activation initiate fibrin deposition, complement signalling, and release of damage-associated molecular patterns (DAMPs). Neutrophils, monocytes, and macrophages dominate early, followed by lymphocytes and vascular smooth muscle cells that remodel the repair compartment. Drug-eluting stents (DES) have markedly reduced early neointimal hyperplasia, yet selected late failures still involve delayed endothelial recovery, chronic peristrut inflammation, hypersensitivity, and neoatherosclerotic transformation. Immune biology is useful at the bedside only when interpreted with procedural context, device design, and patient phenotype. Imaging-defined endpoints and paired immune phenotyping are therefore needed to guide treatment by mechanism instead of angiography or isolated biomarkers.